Novo Nordisk’s troubled factory in Indiana that it got from Catalent continues to face contamination issues, with a re-inspection in April finding mammalian hair in finished drugs and water leaks that compromise product sterility.
Novo Nordisk’s troubled factory in Indiana continues to face contamination issues, with a re-inspection in April finding mammalian hair in finished drugs and water leaks …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novo Nordisk’s troubled factory in Indiana that it got from Catalent continues to face contamination issues, with a re-inspection…
Eighteen months after Novo Nordisk purchased a plant in the | Eighteen months after Novo Nordisk purchased a plant in the Czech…
FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations…
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing…
Novo Nordisk invests ~$380M in Czech manufacturing and $29.4M in China; Cellares grows Series D to $327M; Eisai gets support;…
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing…
